Fondata nel 1998 da Leonard A. e Ronald S. Lauder per finanziare gli scienziati più promettenti del mondo accademico e non, nello sviluppo di nuovi farmaci e clinical trials per l’Alzheimer ed altre tipologie di demenza correlate., l’Alzheimer’s Drug Discovery Foundation è focalizzata sulla ricerca translazionale, per tradurre le conoscenze in medicinali, e mira a colmare la mancanza di fondi inerenti: preclinical drug discovery and early-stage clinical trials of potential drug targets, and early detection.
I bandi
Alzheimer’s Drug Discovery Foundation – Prevention pipeline
Through its Prevention beyond the pipeline Program,The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative ...
Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program
Given the pathological heterogeneity of Alzheimer's disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying ...
Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT)
The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease ...
Alzheimer’s Drug Discovery Foundation – Drug Development Program
Through its Drug Development Program the ADDF seeks to support in vivo preclinical studies that advance lead molecules developed for ...
Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT)
L’obiettivo del bando è l’aumento del numero di trattamenti nuovi per la malattia di Alzheimer, le demenze correlate e l'invecchiamento cognitivo ...
Alzheimer’s Drug Discovery Foundation – Prevention beyond the pipeline
Through its Prevention beyond the pipeline Program, the ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological ...
Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program
Given the pathological heterogeneity of Alzheimer's disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying ...
Alzheimer’s Drug Discovery Foundation – Drug Development Program
Through its Drug Development Program the ADDF seeks to support develop therapeutics for Alzheimr's disease and related dementias. Thsi program ...
Accelerating Drug Discovery for Frontotemporal Dementias
he Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support drug discovery ...